Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday. This story matters for Finance & Markets readers tracking expo. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. ExpoNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily expo signal